2nd Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$450,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Corporate Tax Reform, Proposals to reform domestic and international tax structures

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: Federal Trade Commission (FTC); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); SENATE; White House Office; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Trans Pacific Partnership (TPP), Trade Promotion Authority (TPA), General trade issues

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NAWEL LILLIAN ROJKJAER —
NIMISH SHAH —

Contacted: U.S. Trade Representative (USTR); SENATE; Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; White House Office

Copyright/Patent/Trademark CPT

Patent Reform, H.R. 9 Innovation Act, S. 632 The STRONG Act Access for Generics to Inter Partes Review (IPR)

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS)

Bills named: H.R. 9 (114th), S. 632 (114th)

Health Issues HCR

FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes Proposed FDA rule, "Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products," RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act (GDUFA) Generic drug pricing issues, Medicare Part D program and Generic Drugs HR 6 21st Century Cures Act, Innovation for Healthier American Initiative; Issues regarding market exclusivity Drug Supply Chain Security Act implementation of pharmaceutical distribution REMs program, H.R. 2841 FAST generics Act Anaphylaxis awareness, access to epinephrine auto injector Issues related to the antitrust review of Teva Pharmaceuticals Industries, Ltd. offer to acquire Mylan N.V.

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; Federal Trade Commission (FTC); White House Office; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2841 (114th), H.R. 6 (114th)

Budget/Appropriations BUD

PEPFAR, President's Emergency Plan for AIDS Relief funding, Global Fund funding, Generic Drug, Biosimilar User Fees, FY 2016 Budget, FY2016 House and Senate Appropriations (HR 3049, S 1800, HR 3020, S 1695, HR 2772, S 1725) FDA Safety Over Sequestration Act, HR 1078

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: Health & Human Services, Dept of (HHS); SENATE; U.S. Trade Representative (USTR); White House Office; HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC)

Bills named: H.R. 1078 (114th), H.R. 3020 (114th), H.R. 2772 (114th), H.R. 3049 (114th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN NV United Kingdom United Kingdom 100.0% —
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.